Tradestie Institutional Equity Comparison Engine
THOR vs HAE โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
HAE Overall Edge
HAE Captures Institutional Edge (4โ0 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Haemonetics Corporation (HAE) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, THOR trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus HAE at 22.7x Forward P/E and 18.8% operating margin (+9.3% YoY). In options structure, THOR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against HAE sits in UNCLASSIFIED (2nd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
HAE
THOR N/M vs HAE 22.7x Fwd P/E
Growth & Margin Winner
HAE
Op Margin N/A vs 18.8% ยท YoY N/A vs +9.3%
Momentum & Technical Winner
HAE
1Y -1.4% vs +59.8% ยท 52W Pos 2% vs 85%
Options & Structure Winner
HAE
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (2nd %ile IV)
THOR
US Equity
THOR
Institutional Equity
$24.63
-1.7% 1D
Market Cap
N/A
1M Return
-3.92%
1Y Return
-1.43%
Forward P/E
N/M
Unified AI Score
44.5 / 100
HOLD
Tech 27.0
Fund 50.0
Flow 50.0
Mom 60.0
HAE
NYSE
Haemonetics Corporation
Surgical & Medical Instruments & Apparatus
$120.16
-0.17% 1D
Market Cap
$5.5B
1M Return
+3.44%
1Y Return
+59.81%
Forward P/E
22.7x
Unified AI Score
49.2 / 100
HOLD
Tech 40.0
Fund 38.0
Flow 50.0
Mom 21.1
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
THOR -1.43%
HAE +59.81%
Spread: +66.53 pp (HAE Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
THOR TTM Op. Margin: N/A
HAE TTM Op. Margin: 18.8%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on THOR vs HAE. Trailing 12-month operating profitability (THOR N/A vs HAE 18.8%) and valuation multiples (THOR N/M vs HAE 22.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | THOR | HAE | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $5.5B | Larger Scale | HAE |
| Trailing P/E Ratio Valuation | N/M | 53.3x | Lower Multiple | HAE |
| Forward P/E Ratio Valuation | N/M | 22.7x | Lower Multiple | HAE |
| Revenue Growth (YoY) Growth | N/A | +9.3% | Higher Growth | HAE |
| Operating Margin (TTM) Profitability | N/A | 18.8% | Higher Margin | HAE |
| Net Profit Margin Profitability | N/A | 7.5% | Higher Margin | HAE |
| Return on Equity (ROE) Capital Efficiency | N/A | 11.9% | Higher ROE | HAE |
| 52-Week Range Position Momentum | 2% ($25โ$29) | 85% ($51โ$132) | Stronger Trend | HAE |
| Beta / 30D Volatility Risk Regime | 0.46ฮฒ ยท 17% Vol | 0.28ฮฒ ยท 33% Vol | Lower Realized Risk | THOR |
| Unified Institutional Score Composite Signal | 44.5 / 100 (HOLD) | 49.2 / 100 (HOLD) | Higher Composite | HAE |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full THOR vs HAE Buy Guide
THOR
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
HAE
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
2nd %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither THOR nor HAE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.